PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
26998348-0	2015	The MDM2 small-molecule inhibitor RG7388 leads to potent tumor inhibition in p53 wild-type neuroblastoma.	RG7388	34-40	transformation related protein 53, pseudogene	Mus musculus	77-80	
31311404-0	2019	MDM2 inhibitor RG7388 potently inhibits tumors by activating p53 pathway in nasopharyngeal carcinoma.	RG7388	15-21	transformation related protein 53, pseudogene	Mus musculus	61-64	
27353420-2	2016	In this study, we deliver the rationale and molecular basis for the combination of idasanutlin and venetoclax for treatment of p53 wild-type AML.	RG7388	83-94	transformation related protein 53, pseudogene	Mus musculus	127-130	
27353420-6	2016	RESULTS: Combination treatment with venetoclax and idasanutlin results in synergistic anti-tumor activity compared with the respective single-agent treatments in vitro, in p53 wild-type AML cell lines, and leads to strongly superior efficacy in vivo, in subcutaneous and orthotopic AML models.	RG7388	51-62	transformation related protein 53, pseudogene	Mus musculus	172-175	
27353420-9	2016	As expected, gene expression studies using RNA sequencing showed significant alterations to pathways associated with p53 signaling and cell cycle arrest (CCND1 pathway) in response to idasanutlin treatment.	RG7388	184-195	transformation related protein 53, pseudogene	Mus musculus	117-120